Company news
Ventripoint Diagnostics Ltd. (TSXV:VPT) news
Ventripoint Diagnostics Ltd. news releases on 6ix. Latest, Dec 12, 2025: Healthcare AI Exits Pilot Phase, Enters Production Deployment
Press releases — page 2
Healthcare AI Exits Pilot Phase, Enters Production Deployment
December 12, 2025
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
December 12, 2025
Ventripoint Unveils a Global Model for A.I.-Enhanced Heart Care through Partnership with the Nisga'a Valley Health Authority
December 12, 2025
From Hype to P&L: Hospitals Now Buying AI That Pays
December 8, 2025
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
December 6, 2025
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
December 3, 2025
Ventripoint Diagnostics Announces Appointment of David Swetlow as Chief Financial Officer
December 3, 2025
CEO.CA's Inside the Boardroom: Ventripoint Diagnostics: We Made Ultrasound as Good as MRI - Now Here's How We Scale It
November 27, 2025
Ventripoint Announces Debt Settlement Agreements
November 6, 2025
Ventripoint Diagnostics and Providence Health Care Ventures Announce Collaboration to Validate AI-Enabled Cardiac Imaging at St. Paul's Hospital
October 29, 2025
Ventripoint Provides Corporate Update and Announces Shareholder Teleconference
October 24, 2025
Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Convertible Debenture Units Private Placement
October 14, 2025
Ventripoint Announces Extension and Up Size of Non-Brokered Convertible Debenture Unit Private Placement
October 3, 2025
Ventripoint Announces Successful Completion of Key Quality Audits
September 19, 2025
Ventripoint Announces Closing of First Tranche of Non-Brokered Convertible Debenture Unit Private Placement
September 3, 2025
Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement and Share Issuance
August 26, 2025
Ventripoint Diagnostics Appoints Thomas Brown as Director of Congenital Heart Defect Program
August 18, 2025
Ventripoint Diagnostics Launches Targeted Congenital Heart Defect Marketing Program, Setting Stage for Multi-Segment Growth
August 15, 2025
CEO.CA's Inside the Boardroom: Cardiac MRI Alternative Gets FDA Nod - Ventripoint CEO on U.S. and China Sales Plans
August 13, 2025
Lishman Global Places First Order for Ventripoint's VMS+ Technology
July 28, 2025
Ventripoint and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology
July 11, 2025
Ventripoint Partners with Fournel Advisory
June 17, 2025
Ventripoint Issues Option Grants and Reports Exercise of Options
June 17, 2025
Ventripoint to Exhibit at the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
May 28, 2025
Ventripoint Expands Advisory Board with addition of Ultrasound AI Executive
April 30, 2025
Ventripoint Appoints Nicolas Coutin to Oversee Clinical Affairs
April 8, 2025
Ventripoint Makes Application to Amend Warrants
April 3, 2025
Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis
March 24, 2025
Ventripoint Announces Closing of $500,000 Non-Brokered Convertible Debenture Unit Private Placement
March 21, 2025
Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement
March 14, 2025
Ventripoint Diagnostics Announces U.S. FDA 510(k) Clearance for VMS+(TM) 4.0 Automated Radiological Image Processing Software/System
February 27, 2025
Ventripoint Announces Closing of Third Tranche of Amended Non-Brokered Convertible Debenture Private Placement and Extension of Offering
February 10, 2025
Ventripoint Strengthens Sales Strategy with Global Expertise to Drive 2025 Growth
January 30, 2025
Ventripoint Provides 2025 Update and Outlook
January 23, 2025
Ventripoint Updates Submission to U.S. Food and Drug Administration for its Next Generation, AI-powered Heart-scanning Technology
January 21, 2025
Ventripoint Announces Closing of Second Tranche of Amended Non-Brokered Convertible Debenture Private Placement and Extension of Offering
January 20, 2025
Ventripoint Announces Extension of Non-Brokered Convertible Debenture Private Placement
December 20, 2024
VENTRIPOINT and ASCEND Cardiovascular sign Term Sheet for integration of VMS+ into ASCEND's Gen3Echo(TM) platform
December 18, 2024
Ventripoint Announces Closing of First Tranche of Amended Non-Brokered Convertible Debenture Private Placement
December 17, 2024
Ventripoint Issue Shares for Payment of Debenture Interest and Amends Terms of Convertible Debenture Offering
December 9, 2024
Ventripoint Announces Closing of Debt Settlement Agreements
November 22, 2024
Ventripoint Announces New Sales Program to Accelerate Growth in U.S. Market for AI-Powered Echocardiography Solutions
November 19, 2024
Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption
November 14, 2024
Ventripoint Announces Amended Non-Brokered Convertible Debenture Private Placement and Shares for Debt Transaction
November 6, 2024
Ventripoint Receives EU CE Mark for Next Generation, AI-powered Heart-scanning Technology
October 24, 2024
Ventripoint Announces Closing of First Tranche of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption
October 18, 2024
Ventripoint Announces Extension of Private Placement Offerings and Upsize of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption
October 15, 2024
Ventripoint's Next Generation, AI-powered Heart-Scanning Technology Submitted for EU Medical Device Regulation Certification
October 11, 2024
Ventripoint Selected as Trusted Solution for Cardiac Imaging; Featured at the Take Heart Conference
September 30, 2024
Ventripoint Announces Closing of First Tranche of Non-Brokered Convertible Debenture Private Placement
September 20, 2024